The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use

Gregory P Kaufman,1 Kay M Ristow,1,2 Svetomir N Markovic,1,2 Luis F Porrata1,2 1Department of Internal Medicine, 2Division of Hematology, Mayo Clinic, Rochester, MN, USA Abstract: Risk stratification of patients with classical Hodgkin lymphoma (cHL) remains suboptimal. The ratio of the absolute ly...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kaufman GP, Ristow KM, Markovic SN, Porrata LF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/7fd25cc8e5eb42a7bd9fa81a4f9a54ee
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7fd25cc8e5eb42a7bd9fa81a4f9a54ee
record_format	dspace
spelling	oai:doaj.org-article:7fd25cc8e5eb42a7bd9fa81a4f9a54ee2021-12-02T06:20:25ZThe absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use1179-9889https://doaj.org/article/7fd25cc8e5eb42a7bd9fa81a4f9a54ee2014-07-01T00:00:00Zhttp://www.dovepress.com/the-absolute-lymphocytemonocyte-ratio-recovery-during-abvd-treatment-c-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889 Gregory P Kaufman,1 Kay M Ristow,1,2 Svetomir N Markovic,1,2 Luis F Porrata1,2 1Department of Internal Medicine, 2Division of Hematology, Mayo Clinic, Rochester, MN, USA Abstract: Risk stratification of patients with classical Hodgkin lymphoma (cHL) remains suboptimal. The ratio of the absolute lymphocyte count (ALC) to absolute monocyte count (AMC) both at diagnosis and during subsequent recovery from serial cycles of chemotherapy predicts survival in cHL, and possesses advantages over other commonly used prognostic markers. Myeloid growth factors (MGFs), while not strongly recommended for use in adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) treatment cycles, are not uncommonly used to prevent the negative consequences of neutropenia. The effect that MGFs have on the ALC/AMC ratio during ABVD treatment cycles, if any, remains unclear. We retrospectively evaluated 208 patients with cHL, who were diagnosed, treated, and followed at Mayo Clinic Rochester between 1990 and 2014, and who had quantifiable records for the use of MGFs during ABVD treatment cycles. Having an ALC/AMC ratio <1.1 during all treatment cycles was confirmed as being a negative predictor of overall and progression free survival (hazard ratio [HR] 0.06, 95% confidence interval [CI] 0.03–0.14 and HR 0.08, 95% CI 0.04–0.17, respectively). Data on both the ALC/AMC ratio and use of MGFs were available for 1,979 half treatment cycles. When stratified to whether or not MGFs were given, the change in the ALC/AMC ratio as compared to the prior half cycle was found to be statistically insignificant (P=0.3445). No survival advantage was found with the administration of MGFs in any cycle of therapy (log rank P=0.5713). Our data validate the prognostic significance of having an ALC/AMC ratio of ≥1.1 regardless of the use of MGFs. Keywords: myeloid growth factors, classical Hodgkin lymphoma, survival ALC/AMC ratio, ABVD chemotherapyKaufman GPRistow KMMarkovic SNPorrata LFDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 39-44 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Kaufman GP Ristow KM Markovic SN Porrata LF The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use
description	Gregory P Kaufman,1 Kay M Ristow,1,2 Svetomir N Markovic,1,2 Luis F Porrata1,2 1Department of Internal Medicine, 2Division of Hematology, Mayo Clinic, Rochester, MN, USA Abstract: Risk stratification of patients with classical Hodgkin lymphoma (cHL) remains suboptimal. The ratio of the absolute lymphocyte count (ALC) to absolute monocyte count (AMC) both at diagnosis and during subsequent recovery from serial cycles of chemotherapy predicts survival in cHL, and possesses advantages over other commonly used prognostic markers. Myeloid growth factors (MGFs), while not strongly recommended for use in adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) treatment cycles, are not uncommonly used to prevent the negative consequences of neutropenia. The effect that MGFs have on the ALC/AMC ratio during ABVD treatment cycles, if any, remains unclear. We retrospectively evaluated 208 patients with cHL, who were diagnosed, treated, and followed at Mayo Clinic Rochester between 1990 and 2014, and who had quantifiable records for the use of MGFs during ABVD treatment cycles. Having an ALC/AMC ratio <1.1 during all treatment cycles was confirmed as being a negative predictor of overall and progression free survival (hazard ratio [HR] 0.06, 95% confidence interval [CI] 0.03–0.14 and HR 0.08, 95% CI 0.04–0.17, respectively). Data on both the ALC/AMC ratio and use of MGFs were available for 1,979 half treatment cycles. When stratified to whether or not MGFs were given, the change in the ALC/AMC ratio as compared to the prior half cycle was found to be statistically insignificant (P=0.3445). No survival advantage was found with the administration of MGFs in any cycle of therapy (log rank P=0.5713). Our data validate the prognostic significance of having an ALC/AMC ratio of ≥1.1 regardless of the use of MGFs. Keywords: myeloid growth factors, classical Hodgkin lymphoma, survival ALC/AMC ratio, ABVD chemotherapy
format	article
author	Kaufman GP Ristow KM Markovic SN Porrata LF
author_facet	Kaufman GP Ristow KM Markovic SN Porrata LF
author_sort	Kaufman GP
title	The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use
title_short	The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use
title_full	The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use
title_fullStr	The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use
title_full_unstemmed	The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use
title_sort	absolute lymphocyte/monocyte ratio recovery during abvd treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical hodgkin lymphoma regardless of their use
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/7fd25cc8e5eb42a7bd9fa81a4f9a54ee
work_keys_str_mv	AT kaufmangp theabsolutelymphocytemonocyteratiorecoveryduringabvdtreatmentcyclesisnotsignificantlyimpactedbytheuseofmyeloidgrowthfactorsandpredictsclinicaloutcomesinclassicalhodgkinlymphomaregardlessoftheiruse AT ristowkm theabsolutelymphocytemonocyteratiorecoveryduringabvdtreatmentcyclesisnotsignificantlyimpactedbytheuseofmyeloidgrowthfactorsandpredictsclinicaloutcomesinclassicalhodgkinlymphomaregardlessoftheiruse AT markovicsn theabsolutelymphocytemonocyteratiorecoveryduringabvdtreatmentcyclesisnotsignificantlyimpactedbytheuseofmyeloidgrowthfactorsandpredictsclinicaloutcomesinclassicalhodgkinlymphomaregardlessoftheiruse AT porratalf theabsolutelymphocytemonocyteratiorecoveryduringabvdtreatmentcyclesisnotsignificantlyimpactedbytheuseofmyeloidgrowthfactorsandpredictsclinicaloutcomesinclassicalhodgkinlymphomaregardlessoftheiruse AT kaufmangp absolutelymphocytemonocyteratiorecoveryduringabvdtreatmentcyclesisnotsignificantlyimpactedbytheuseofmyeloidgrowthfactorsandpredictsclinicaloutcomesinclassicalhodgkinlymphomaregardlessoftheiruse AT ristowkm absolutelymphocytemonocyteratiorecoveryduringabvdtreatmentcyclesisnotsignificantlyimpactedbytheuseofmyeloidgrowthfactorsandpredictsclinicaloutcomesinclassicalhodgkinlymphomaregardlessoftheiruse AT markovicsn absolutelymphocytemonocyteratiorecoveryduringabvdtreatmentcyclesisnotsignificantlyimpactedbytheuseofmyeloidgrowthfactorsandpredictsclinicaloutcomesinclassicalhodgkinlymphomaregardlessoftheiruse AT porratalf absolutelymphocytemonocyteratiorecoveryduringabvdtreatmentcyclesisnotsignificantlyimpactedbytheuseofmyeloidgrowthfactorsandpredictsclinicaloutcomesinclassicalhodgkinlymphomaregardlessoftheiruse
_version_	1718399943794753536

The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use

Ejemplares similares